• Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. Boumans M, Teng O, Thurlings R, Bijlsma J, Gerlag D, Huizinga T, Vos K, Stapel S, Wolbink G, Tekstra J, van Laar J, Tak PP. Rheumatology (Oxford). 2013 Aug;52(8):1462-6.

 

  • A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis. van den Bemt BJ, Vos K, den Broeder AA, Blom M, Thurlings RM, Bartelds GM, Stapel SO, Barrera P, Tak PP, Nurmohamed MT, Wolbink GJ. Ann Rheum Dis 2009; 68(8):1368-9.

 

  • Clinical response, pharmacokinetics, development of human anti-chimeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ. Ann Rheum Dis 2009 Jul 12.  

 

  • Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H. Arthritis Rheum 2005; 52(9):2740-50